Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab

BACKGROUND: Although PD-1 antibodies (PD1 Ab) are the standard of care for advanced non-small-cell lung cancer (ansclc), most patients will progress. We compared survival outcomes for patients with ansclc who received systemic therapy (st) after progression and for those who did not. Additionally, c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Oncol
Main Authors: Freeman, A.T., Lesperance, M., Wai, E.S., Croteau, N.S., Fiorino, L., Geller, G., Brooks, E.G., Poonja, Z., Fenton, D., Irons, S., Ksienski, D.
Formato: Artigo
Idioma:Inglês
Publicado em: Multimed Inc. 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7253749/
https://ncbi.nlm.nih.gov/pubmed/32489249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.5495
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados